Compare LBRDK & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDK | CYTK |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | LBRDK | CYTK |
|---|---|---|
| Price | $47.74 | $63.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $77.87 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 5.51 | N/A |
| Revenue | ★ $1,016,000,000.00 | $87,211,000.00 |
| Revenue This Year | N/A | $361.33 |
| Revenue Next Year | $37.46 | $65.14 |
| P/E Ratio | $8.52 | ★ N/A |
| Revenue Growth | 306.40 | ★ 2609.26 |
| 52 Week Low | $44.63 | $29.31 |
| 52 Week High | $104.00 | $69.33 |
| Indicator | LBRDK | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 47.90 |
| Support Level | $44.88 | $63.50 |
| Resistance Level | $48.06 | $67.26 |
| Average True Range (ATR) | 1.34 | 2.66 |
| MACD | 0.64 | -0.59 |
| Stochastic Oscillator | 88.63 | 33.81 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.